Clozapine alone versus clozapine and risperidone with refractory schizophrenia

William G. Honer, Allen E. Thornton, Eric Y.H. Chen, Raymond C.K. Chan, Jessica O.Y. Wong, Andrea Bergmann, Peter Falkai, Edith Pomarol-Clotet, Peter J. McKenna, Emmanuel Stip, Richard Williams, G. William MacEwan, Kishor Wasan, Ric Procyshyn

Research output: Contribution to journalArticlepeer-review

224 Citations (Scopus)

Abstract

BACKGROUND: The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known. METHODS: In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course of treatment was followed by an optional 18 weeks of augmentation with risperidone. The primary outcome was reduction in the total score for severity of symptoms on the Positive and Negative Syndrome Scale (PANSS). The secondary outcomes included cognitive functioning. RESULTS: A total of 68 patients were randomly assigned to treatment. In the double-blind phase, the mean total score for the severity of symptoms decreased from baseline to eight weeks in both the risperidone and the placebo groups. There was no statistically significant difference in symptomatic benefit between augmentation with risperidone and placebo: 9 of 34 patients receiving placebo and 6 of 34 receiving risperidone responded to treatment (P = 0.38). The mean difference in the change in PANSS scores from baseline to eight weeks between those receiving risperidone and those receiving placebo was 0.1 (95 percent confidence interval, -7.3 to 7.0). The verbal working-memory index showed a small decline in the risperidone group and a small improvement in the placebo group (P = 0.02 for the comparison between the two groups in the change from baseline). The increase in fasting blood glucose levels was mildly greater in the risperidone group than in the placebo group (16.2 vs. 1.8 mg per deciliter [0.90 vs. 0.10 mmol per liter], P = 0.04). The incidence and severity of other side effects did not differ between the two groups. CONCLUSIONS: In this short-term study, the addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia. (ClinicalTrials.gov number, NCT00272584)

Original languageEnglish
Pages (from-to)472-482
Number of pages11
JournalNew England Journal of Medicine
Volume354
Issue number5
DOIs
Publication statusPublished - Feb 2 2006
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Clozapine alone versus clozapine and risperidone with refractory schizophrenia'. Together they form a unique fingerprint.

Cite this